Filing Flows › TG Therapeutics (TGTX) › Next earnings date
TG Therapeutics (TGTX) earnings on Nov 9, 2026: what to expect
TG Therapeutics (TGTX) is expected to report earnings on Nov 9, 2026, tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of $0.26 ($0.19 to $0.35, 4 estimates) on revenue of $245M, against $0.16 and $162M a year ago. It beat the EPS estimate in 0% of the quarters on record; Filing Flows' model gives it a 34% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS $0.34 on revenue of $282M, against the analysts' $0.26.
The last report
TG Therapeutics reported revenue of $240M for the second quarter 2026 (+70% Y/Y), net earnings $7.8M: Product $236M, License $4.5M. How it makes money → · Every quarter →
TG Therapeutics' latest quarter
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
When does TGTX report earnings?
TG Therapeutics is expected to report on Nov 9, 2026.
What are analysts expecting from TG Therapeutics?
EPS of $0.26 and revenue of $245M for the quarter.
Does TG Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 0% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.